These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24359588)

  • 21. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.
    Lu JP; Knudson MM; Bir N; Kallet R; Atkinson K
    J Am Coll Surg; 2009 Nov; 209(5):589-94. PubMed ID: 19854398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.
    Nutescu EA; Wittkowsky AK; Dobesh PP; Hawkins DW; Dager WE
    Ann Pharmacother; 2006 Sep; 40(9):1558-71. PubMed ID: 16912250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fondaparinux.
    Tan KT; Lip GY
    Curr Pharm Des; 2005; 11(4):415-9. PubMed ID: 15725062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thromboprophylaxis in medical patients--why not for all?
    Schulman S
    Pathophysiol Haemost Thromb; 2006; 35(1-2):141-5. PubMed ID: 16855360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fondaparinux in the initial and long-term treatment of venous thromboembolism.
    Pesavento R; Amitrano M; Trujillo-Santos J; Di Micco P; Mangiacapra S; López-Jiménez L; Falgá C; García-Bragado F; Piovella C; Prandoni P; Monreal M;
    Thromb Res; 2015 Feb; 135(2):311-7. PubMed ID: 25543161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing postsurgical venous thromboembolism: pharmacological approaches.
    Tufano A; Coppola A; Cerbone AM; Ruosi C; Franchini M
    Semin Thromb Hemost; 2011 Apr; 37(3):252-66. PubMed ID: 21455859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Traditional versus modern anticoagulant strategies: summary of the literature.
    Nutescu E; Racine E
    Am J Health Syst Pharm; 2002 Oct; 59(20 Suppl 6):S7-14. PubMed ID: 12400244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    ; Mehta SR; Yusuf S; Granger CB; Wallentin L; Peters RJ; Bassand JP; Budaj A; Joyner C; Chrolavicius S; Fox KA
    Am Heart J; 2005 Dec; 150(6):1107. PubMed ID: 16338245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and experimental experience with factor Xa inhibitors.
    Viles-Gonzalez JF; Gaztanaga J; Zafar UM; Fuster V; Badimon JJ
    Am J Cardiovasc Drugs; 2004; 4(6):379-84. PubMed ID: 15554723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
    Bauer KA; Hawkins DW; Peters PC; Petitou M; Herbert JM; van Boeckel CA; Meuleman DG
    Cardiovasc Drug Rev; 2002; 20(1):37-52. PubMed ID: 12070533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?
    Squizzato A; Romualdi E; Dentali F; Ageno W
    Curr Opin Anaesthesiol; 2010 Dec; 23(6):722-5. PubMed ID: 20847691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.